The Benchmark Company Sees Xenotis Acquisition As Good For LeMaitre Vascular

By: via Benzinga
In a report published Tuesday, The Benchmark Company analyst Jan Wald reiterated a Buy rating and $11.00 price target on LeMaitre ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.